UK-based SkyePharma plc has acquired a 40.2% interest in RTP Pharma Inc for US$20 million and has participated in a $15-million equity infusion to fund ongoing operations. The involvement of SkyePharma will assist the Montreal-based firm in expanding its market position through strategic project collaboration and access to Skye’s expertise in controlled release and inhalation technologies. RTP is a leader in the formulation of water-insoluble drugs. It’s Insoluble Drug Delivery (IDD) IDD technology platform helps to overcome problems of insolubility by enhancing the uptake and safety of water-soluble drugs across a range of therapeutic classes. Also participating in the financing is Innovatech du Grand Montréal, which invested $1.7 million....